NEXR-TECHNOLOGIES-SE
30.9.2021 18:49:09 CEST | Business Wire | Press release
NeXR Technologies SE (XETRA: NXR ) has reached one more milestone in its groundbreaking cooperation with H&Mbeyond. By installing the Fusion III body scanner developed by NeXR Technologies and starting the test phase of the AvatarCloud Fashion application, H&M Germany is opening selected stores for virtual fitting of its new collection. From 14 October to 6 November this year, H&M customers will have the opportunity to virtually try on perfect-fit looks from the new collection from home and outside of store opening hours via "digital fitting rooms" in two stores in Berlin and one H&M store in Hamburg.
As part of the test phase, customers can have a personal avatar, a digital twin, created free of charge with their exact body measurements in the scanners of participating H&M stores. The innovative AvatarCloud app from NeXR Technologies allows customers to try on the matching styles of around 30 pieces of apparel from the new collection on their own avatar. An expansion of the virtual fitting offer to further collections is already technically possible.
NeXR Technologies SE: H&M Germany opens selected stores for virtual fitting with AvatarCloud app
The technology, developed by NeXR and driven forward in collaboration with H&Mbeyond. for use in fashion retail, strives not only to offer an exciting digital shopping experience but also to analyze together with customers what impact "digital fitting rooms" can have on shopping behavior. H&Mbeyond. the Berlin-based innovation lab of H&M Germany, is responsible for developing and piloting innovative products and services relevant to H&M's global organization.
Markus Peuler, Managing Director of NeXR Technologies SE: "We are very proud that H&Mbeyond. awarded us as a trusted partner in their innovation work immediately with the test operation in three of their major stores. With our Virtual Fitting solution for H&M Germany, we have reached another milestone in the roll-out of our products announced for the current financial year. We are confident that this cooperation will also enable us to make a long-term contribution to sustainability in the textile industry. That is a very important matter for us."
The AvatarCloud app is available on the Apple AppStore and Google Play . For more information on AvatarCloud and the new H&M collection, please visit: avatar.cloud .
About NeXR Technologies
NeXR Technologies SE from Berlin (XETRA: NXR ) is a listed technology company with a focus on virtual reality applications. The core of the company consists of personalized, digital avatars that support users in performing everyday tasks more efficiently. These include the visualization of training successes on one's own avatar (NeXR Fitness), the virtual fitting of clothing (NeXR Fashion) or the participation in and the design of virtual live events (NeXR Show) and remote presentations (NeXR Seminar). NeXR Technologies has core competencies in 3D scanner development, motion capture, virtual reality, virtual production as well as deep understanding in gaming and data-based business models. Based on two self-developed multi-user and multi-purpose platforms, NeXR Technologies offers products and solutions for numerous user industries. NeXR Technologies SE is listed in the General Standard of the Frankfurt Stock Exchange. For more information, please visit www.nexr-technologies.com .
About H&M
H & M Hennes & Mauritz AB (publ) was founded in Sweden in 1947 and is quoted on Nasdaq Stockholm. H&M's business idea is to offer fashion and quality at the best price in a sustainable way. In addition to H&M, the group includes the brands COS, Monki, Weekday, & Other Stories, H&M HOME and ARKET as well as Afound. The H&M group has 51 online markets and more than 5,000 stores in 74 markets including franchise markets. In 2019, net sales were SEK 233 billion. The number of employees amounts to more than 179,000. For further information, visit hmgroup.com .
Language: |
English |
Company: |
NEXR Technologies SE |
Charlottenstraße 4 |
|
10969 Berlin |
|
Germany |
|
Phone: |
+49 (0) 30 403 680 143 |
Fax: |
+49 (0) 30 403 680 141 |
E-mail: |
|
Internet: |
|
ISIN: |
DE000A1K03W5 |
WKN: |
A1K03W |
Listed: |
Regulated Market in Berlin, Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom